Trial reportAntimicrobial agents and chemotherapy2008
Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.
Trial report in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 3 syntheses or guidelines pooled it, 295 citations in OpenAlex.
- β-lactam antibiotics vs vancomycin in treating methicillin-sensitive staphylococcus aureus bloodstream infections: a meta-analysis of clinical outcomes.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Pooled it
- Female Sex and Mortality in Patients with Staphylococcus aureus Bacteremia: A Systematic Review and Meta-analysis.JAMA network open · 2024Pooled it
- Effect of the vancomycin minimum inhibitory concentration on clinical outcomes in patients with methicillin-susceptibleBMJ open · 2021Pooled it
- Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Antimicrobial agents and chemotherapy · 2019Trial
- Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.BMJ (Clinical research ed.) · 2015Trial
- Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.The Journal of antimicrobial chemotherapy · 2008Trial
- Impact of a standardized management protocol and antimicrobial stewardship intervention on mortality and quality of care in Staphylococcus aureus bacteremia: a before-after study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The Clinical Impact of Antibiotic Allergy Labels on One-Year Outcomes of Solid Organ Transplant Recipients.Clinical transplantation · 2026Article
- Ethanol lock therapy for salvage of infected tunnelled haemodialysis catheters: a randomised controlled trial.Clinical kidney journal · 2026Article
- The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies.Infectious diseases and therapy · 2026Review
- Impact of rapid molecular testing on clinical outcomes for methicillin-susceptibleAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Fatal Catheter-Related Hematogenous Disseminated MSSA Sepsis in an Immunocompromised Lung Cancer Patient: A Case Report.Infection and drug resistance · 2026Article
- Bridging the gap in bloodstream infection management: a survey among non-infectious disease physicians.JAC-antimicrobial resistance · 2025Article
- ROS-Driven Nanoventilator for MRSA-Induced Acute Lung Injury Treatment via In Situ Oxygen Supply, Anti-Inflammation and Immunomodulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Bloodstream infections: mechanisms of pathogenesis and opportunities for intervention.Nature reviews. Microbiology · 2025Review
- Acute Bacterial Sacroiliitis With Associated Iliacus Abscess in a Healthy Young Woman: A Case Report.Case reports in infectious diseases · 2025Article
- Pharmacist-led antimicrobial stewardship program in the treatment ofInfection prevention in practice · 2024Article
- Clinical outcome of ampicillin or ampicillin/sulbactam versus glycopeptides in ampicillin-susceptible Enterococcus faecalis/faecium bacteremia: a 10-year retrospective cohort study.BMC infectious diseases · 2024Article
- Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study.Drugs - real world outcomes · 2024Article
- Assessing the Interpretation of Molecular Test Results in the Diagnosis of Bloodstream Infections.Diagnostics (Basel, Switzerland) · 2024Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited data on the clinical outcome of vancomycin treatment compared with that of beta-lactam treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia (MSSA-B) are available. We used different and complementary approaches: (i) a retrospective cohort study using a propensity score to adjust for confounding by treatment assignment and (ii) a matched case-control study. Of all patients with S. aureus bacteremia (SAB) in two university-affiliated hospitals over a 7-year period, 294 patients with MSSA-B were enrolled in the cohort study. The cases for the case-control study were defined as patients who received vancomycin treatment for MSSA-B; the controls, who were patients that received beta-lactam treatment for MSSA-B, were selected at a 1:2 (case:control) ratio according to the objective matching scoring system and the propensity score system. In the cohort study, SAB-related mortality in patients with vancomycin treatment (37%, 10/27) was significantly higher than that in those with beta-lactam treatment (18%, 47/267) (P = 0.02). In addition, multivariate analysis revealed that vancomycin treatment was associated with SAB-related mortality when independent predictors for SAB-related mortality and propensity score were considered (adjusted odds ratio of 3.3, 95% confidence interval of 1.2 to 9.5). In the case-control study using the objective matching scoring system and the propensity score system, SAB-related mortality in case patients was 37% (10/27) and in control patients 11% (6/54) (P < 0.01). Our data suggest that vancomycin is inferior to beta-lactam in the treatment of MSSA-B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.